Physician profile
Sabrina Budden-Wright
NPI 1376205856
$2,648.29
in general payments reported to CMS, 2019-2025
20 companies · $33.42 in 2025
The $33.42 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $661 · 2023: $1,352 · 2024: $602 · 2025: $33.42.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,987.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,987.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $419.15 | 2022-2024 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Lundbeck LLC | $287.61 | 2022-2024 | Rexulti |
| Abbvie INC. | $279.22 | 2022-2024 | |
| Alkermes, INC. | $259.54 | 2022-2024 | Aristada, Lybalvi, Vivitrol |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $245.39 | 2022-2024 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $221.95 | 2022-2024 | Uzedy, Austedo |
| Vanda Pharmaceuticals INC. | $201.51 | 2022-2023 | Fanapt, Hetlioz |
| Indivior INC. | $149.32 | 2022-2024 | Perseris, Sublocade |
| Noven Therapeutics, LLC | $117.20 | 2023-2024 | Secuado, Xelstrym |
| Janssen Pharmaceuticals, INC | $115.58 | 2022-2024 | Invega Sustenna, Spravato, Invega Trinza |
| Corium, LLC | $91.33 | 2022-2024 | Azstarys |
| Axsome Therapeutics, INC. | $83.14 | 2022-2024 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $34.43 | 2022 | |
| Medtronic, INC. | $33.42 | 2025 | Minimed 780g |
| Neurocrine Biosciences, INC. | $30.14 | 2024 | Ingrezza |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $21.46 | 2023 | Qelbree |
| Tris Pharma INC | $17.35 | 2023 | Dyanavel Xr |
| Idorsia Pharmaceuticals US INC | $14.77 | 2023 | Quviviq |
| Sage Therapeutics, LLC | $13.30 | 2024 | |
| Avanir Pharmaceuticals, INC. | $12.48 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sabrina Budden-Wright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.